Myostatin, which was cloned in 1997, is a potent inhibitor of skeletal muscle growth and
member of the tumour growth factor-β family. Disruption of the myostatin gene in mice …

Myostatin, a transforming growth factor–β family member, is a negative regulator of skeletal
muscle growth. To explore the therapeutic potential of targeting myostatin in settings of …

▪ Abstract Myostatin is a secreted protein that acts as a negative regulator of skeletal muscle
mass. During embryogenesis, myostatin is expressed by cells in the myotome and in …

Both acquired and inherited disorders of muscle are common; thus, greater understanding of
muscle growth and maintenance is important for future therapies. Myostatin down-regulates …

Myostatin is a negative regulator of skeletal muscle growth. Myostatin mutations and
pharmacological strategies increase muscle mass in vivo, suggesting that myostatin …

Previous findings have provided strong evidence that myostatin functions as a negative
regulator of muscle mass during development and growth. In the present study, we test the …

Myostatin is a master regulator of myogenesis and early postnatal skeletal muscle growth.
However, myostatin has been also involved in several forms of muscle wasting in adulthood …

Myostatin deficiency leads to both an increased rate of protein synthesis and skeletal muscle
hypertrophy. However, the mechanisms involved in mediating these effects are not yet fully …

Since its discovery in 1997, myostatin has quickly been established as a key regulator of
skeletal muscle mass. Recent developments strengthen the idea that myostatin will be an …

Myostatin is a secreted protein that normally acts to limit skeletal muscle growth. As a result,
there is considerable interest in developing agents capable of blocking myostatin activity, as …